BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang J, Zhang X, Tang Q, Zhang F, Li Y, Feng Z, Zhu J. Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol 2011;64:343-8. [DOI: 10.1136/jcp.2010.085142] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med. 2011;32:88-111. [PMID: 21565214 DOI: 10.1016/j.mam.2011.04.004] [Cited by in Crossref: 130] [Cited by in F6Publishing: 127] [Article Influence: 11.8] [Reference Citation Analysis]
2 Lu M, Zhu H, Wang X, Zhang D, Xiong L, Xu L, You Y. The prognostic role of Eg5 expression in laryngeal squamous cell carcinoma. Pathology 2016;48:214-8. [DOI: 10.1016/j.pathol.2016.02.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
3 Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, Okusaka T, Kubackova K, Trojan J, Sastre J, Chau I, Chang SC, Abada PB, Yang L, Schwartz JD, Kudo M; REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 2015;16:859-70. [PMID: 26095784 DOI: 10.1016/S1470-2045(15)00050-9] [Cited by in Crossref: 419] [Cited by in F6Publishing: 246] [Article Influence: 59.9] [Reference Citation Analysis]
4 Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34252328 DOI: 10.1080/14656566.2021.1953473] [Reference Citation Analysis]
5 Sugimoto K, Moriyasu F, Negishi Y, Hamano N, Oshiro H, Rognin NG, Yoshida T, Kamiyama N, Aramaki Y, Imai Y. Quantification in Molecular Ultrasound Imaging: A Comparative Study in Mice Between Healthy Liver and a Human Hepatocellular Carcinoma Xenograft. Journal of Ultrasound in Medicine 2012;31:1909-16. [DOI: 10.7863/jum.2012.31.12.1909] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
6 Zhai X, Xu L, Zhang S, Zhu H, Mao G, Huang J. High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma. Oncotarget 2016;7:4871-81. [PMID: 26717042 DOI: 10.18632/oncotarget.6741] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
7 Bösmüller H, Pfefferle V, Bittar Z, Scheble V, Horger M, Sipos B, Fend F. Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Pathol Res Pract 2018;214:1136-41. [PMID: 29935812 DOI: 10.1016/j.prp.2018.06.011] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
8 Yang L, Zhang H, Yao Q, Yan Y, Wu R, Liu M. Clinical Significance of SASH1 Expression in Glioma. Dis Markers 2015;2015:383046. [PMID: 26424902 DOI: 10.1155/2015/383046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
9 Thompson JJ, Morrison JA, Pearl DL, Boston SE, Wood GA, Foster RA, Coomber BL. Receptor Tyrosine Kinase Expression Profiles in Canine Cutaneous and Subcutaneous Mast Cell Tumors. Vet Pathol 2016;53:545-58. [DOI: 10.1177/0300985815610388] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
10 Chan SL, Wong AM, Lee K, Wong N, Chan AK. Personalized therapy for hepatocellular carcinoma: Where are we now? Cancer Treatment Reviews 2016;45:77-86. [DOI: 10.1016/j.ctrv.2016.02.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 6.7] [Reference Citation Analysis]
11 Zhou L, Rui JA, Wang SB, Chen SG, Qu Q. Risk factors of poor prognosis and portal vein tumor thrombosis after curative resection of solitary hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12:68-73. [PMID: 23392801 DOI: 10.1016/s1499-3872(13)60008-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
12 Feng J, Xu L, Ni S, Gu J, Zhu H, Wang H, Zhang S, Zhang W, Huang J. Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity. Oncotarget 2014;5:9689-702. [PMID: 25356753 DOI: 10.18632/oncotarget.2103] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
13 Dang Q, Zhou H, Qian J, Yang L, Huang J, Zhang Y, Shi W. LAMP1 Overexpression Predicts for Poor Prognosis in Diffuse Large B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 2018;18:749-54. [PMID: 30082222 DOI: 10.1016/j.clml.2018.07.288] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Jiang H, Wu D, Xu D, Yu H, Zhao Z, Ma D, Jin J. Eupafolin Exhibits Potent Anti-Angiogenic and Antitumor Activity in Hepatocellular Carcinoma. Int J Biol Sci 2017;13:701-11. [PMID: 28655996 DOI: 10.7150/ijbs.17534] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
15 Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol 2020;55:627-39. [PMID: 32107609 DOI: 10.1007/s00535-020-01668-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Luchini C, Capelli P, Fassan M, Simbolo M, Mafficini A, Pedica F, Ruzzenente A, Guglielmi A, Corbo V, Scarpa A. Next-generation histopathologic diagnosis: a lesson from a hepatic carcinosarcoma. J Clin Oncol 2014;32:e63-6. [PMID: 24493719 DOI: 10.1200/JCO.2012.47.5855] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
17 Herencia C, Martínez-Moreno JM, Herrera C, Corrales F, Santiago-Mora R, Espejo I, Barco M, Almadén Y, de la Mata M, Rodríguez-Ariza A. Nuclear translocation of β-catenin during mesenchymal stem cells differentiation into hepatocytes is associated with a tumoral phenotype. PLoS One. 2012;7:e34656. [PMID: 22506042 DOI: 10.1371/journal.pone.0034656] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
18 Huang J, Liang J, Tang Q, Wang Z, Chen L, Zhu J, Feng Z. An active murine–human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors. Appl Microbiol Biotechnol 2011;91:1341-51. [DOI: 10.1007/s00253-011-3335-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
19 Lei J, Zhong J, Hao J, Liu Z, Zhang P, Wu L, Yan L, Zhu J, Zeng Y, Li B, Wen T, Wang W. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence. Oncotarget 2016;7:42598-607. [PMID: 26981887 DOI: 10.18632/oncotarget.3799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
20 Yen CC, Yen CJ. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf 2021;:1-10. [PMID: 34668832 DOI: 10.1080/14740338.2022.1995353] [Reference Citation Analysis]
21 Zhou N, Liu C, Wang X, Mao Q, Jin Q, Li P. Downregulated SASH1 expression indicates poor clinical prognosis in gastric cancer. Human Pathology 2018;74:83-91. [DOI: 10.1016/j.humpath.2018.01.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
22 Zhai X, Zhu H, Wang W, Zhang S, Zhang Y, Mao G. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC. Med Oncol. 2014;31:970. [PMID: 24781336 DOI: 10.1007/s12032-014-0970-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 72] [Article Influence: 9.9] [Reference Citation Analysis]
23 Liu L, Qin S, Zheng Y, Han L, Zhang M, Luo N, Liu Z, Gu N, Gu X, Yin X. Molecular targeting of VEGF/VEGFR signaling by the anti-VEGF monoclonal antibody BD0801 inhibits the growth and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. Cancer Biol Ther 2017;18:166-76. [PMID: 28368741 DOI: 10.1080/15384047.2017.1282019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
24 Huang J, Zhu H, Wang X, Tang Q, Huang H, Wu K, Zhu J, Feng Z, Shi G. The patterns and expression of KDR in normal tissues of human internal organs. J Mol Histol 2011;42:597-603. [PMID: 21909756 DOI: 10.1007/s10735-011-9355-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
25 Giovannini C, Baglioni M, Baron Toaldo M, Cescon M, Bolondi L, Gramantieri L. Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma. Sci Rep 2017;7:44685. [PMID: 28322221 DOI: 10.1038/srep44685] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
26 Lian S, Zhai X, Wang X, Zhu H, Zhang S, Wang W, Wang Z, Huang J. Elevated expression of growth-regulated oncogene-alpha in tumor and stromal cells predicts unfavorable prognosis in pancreatic cancer. Medicine (Baltimore) 2016;95:e4328. [PMID: 27472713 DOI: 10.1097/MD.0000000000004328] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
27 D'Haene N, Koopmansch C, Van Eycke YR, Hulet F, Allard J, Bouri S, Rorive S, Remmelink M, Decaestecker C, Maris C, Salmon I. The Prognostic Value of the Combination of Low VEGFR-1 and High VEGFR-2 Expression in Endothelial Cells of Colorectal Cancer. Int J Mol Sci 2018;19:E3536. [PMID: 30423986 DOI: 10.3390/ijms19113536] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
28 Huang J, Tang Q, Wang C, Yu H, Feng Z, Zhu J. Molecularly Targeted Therapy of Human Hepatocellular Carcinoma Xenografts with Radio-iodinated Anti-VEGFR2 Murine-Human Chimeric Fab. Sci Rep 2015;5:10660. [PMID: 26021484 DOI: 10.1038/srep10660] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
29 Chen JL, Wang L, Li R, Jiao YF, Yu WF. High expression of endothelial progenitor cell-induced angiogenic markers is associated with bile acid levels in HCC. Oncol Lett 2020;20:2729-38. [PMID: 32782589 DOI: 10.3892/ol.2020.11815] [Reference Citation Analysis]
30 Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with the phenomenon of EMT. PLoS One 2012;7:e39937. [PMID: 22761930 DOI: 10.1371/journal.pone.0039937] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
31 Chen S, Qin C, Sin JE, Yang X, Tao L, Zeng X, Zhang P, Gao CM, Jiang YY, Zhang C, Chen YZ, Chui WK. Discovery of novel dual VEGFR2 and Src inhibitors using a multistep virtual screening approach. Future Med Chem 2017;9:7-24. [PMID: 27995811 DOI: 10.4155/fmc-2016-0162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
32 Roviello G, Sohbani N, Petrioli R, Rodriquenz MG. Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? Invest New Drugs 2019;37:1274-88. [PMID: 30879152 DOI: 10.1007/s10637-019-00760-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
33 Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology. 2014;60:1264-1277. [PMID: 24849467 DOI: 10.1002/hep.27236] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
34 Kampen KR. The mechanisms that regulate the localization and overexpression of VEGF receptor-2 are promising therapeutic targets in cancer biology. Anticancer Drugs 2012;23:347-54. [PMID: 22261741 DOI: 10.1097/CAD.0b013e32835004ac] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
35 Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, Chieco P, Gramantieri L, Bolondi L. Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. Oncotarget 2013;4:1618-31. [PMID: 24113128 DOI: 10.18632/oncotarget.1221] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 3.8] [Reference Citation Analysis]
36 Thaiss W, Kaufmann S, Kloth C, Nikolaou K, Bösmüller H, Horger M. VEGFR-2 expression in HCC, dysplastic and regenerative liver nodules, and correlation with pre-biopsy Dynamic Contrast Enhanced CT. European Journal of Radiology 2016;85:2036-41. [DOI: 10.1016/j.ejrad.2016.09.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
37 Huang J, Mei H, Tang Z, Li J, Zhang X, Lu Y, Huang F, Jin Q, Wang Z. Triple-amiRNA VEGFRs inhibition in pancreatic cancer improves the efficacy of chemotherapy through EMT regulation. J Control Release 2017;245:1-14. [PMID: 27889393 DOI: 10.1016/j.jconrel.2016.11.024] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
38 Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13:871-882. [PMID: 24263190 DOI: 10.1038/nrc3627] [Cited by in Crossref: 639] [Cited by in F6Publishing: 626] [Article Influence: 79.9] [Reference Citation Analysis]
39 Liu K, Hao M, Ouyang Y, Zheng J, Chen D. CD133+ cancer stem cells promoted by VEGF accelerate the recurrence of hepatocellular carcinoma. Sci Rep 2017;7:41499. [PMID: 28134312 DOI: 10.1038/srep41499] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 5.6] [Reference Citation Analysis]
40 Liu L, Sun H, Wu S, Tan H, Sun Y, Liu X, Si S, Xu L, Huang J, Zhou W, Yang Z, Wang Z. IL‑17A promotes CXCR2‑dependent angiogenesis in a mouse model of liver cancer. Mol Med Rep 2019;20:1065-74. [PMID: 31173199 DOI: 10.3892/mmr.2019.10310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
41 Zheng YB, Meng QW, Zhao W, Liu B, Huang JW, He X, Li Y, Hu BS, Lu LG. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. Med Oncol. 2014;31:843. [PMID: 24442426 DOI: 10.1007/s12032-014-0843-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
42 Miettinen M, Rikala MS, Rys J, Lasota J, Wang ZF. Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol. 2012;36:629-639. [PMID: 22314185 DOI: 10.1097/pas.0b013e318243555b] [Cited by in Crossref: 54] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
43 Baron Toaldo M, Salvatore V, Marinelli S, Palamà C, Milazzo M, Croci L, Venerandi L, Cipone M, Bolondi L, Piscaglia F. Use of VEGFR-2 Targeted Ultrasound Contrast Agent for the Early Evaluation of Response to Sorafenib in a Mouse Model of Hepatocellular Carcinoma. Mol Imaging Biol. 2014;Epub ahead of print. [PMID: 25082536 DOI: 10.1007/s11307-014-0764-x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
44 Han L, Jiang B, Wu H, Wang X, Tang X, Huang J, Zhu J. High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma. Med Oncol. 2012;29:2466-2472. [PMID: 22274915 DOI: 10.1007/s12032-011-0152-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
45 Wang W, He S, Ji J, Huang J, Zhang S, Zhang Y. The prognostic significance of FOXQ1 oncogene overexpression in human hepatocellular carcinoma. Pathology - Research and Practice 2013;209:353-8. [DOI: 10.1016/j.prp.2013.03.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
46 Liu C, Zhou N, Li J, Kong J, Guan X, Wang X. Eg5 Overexpression Is Predictive of Poor Prognosis in Hepatocellular Carcinoma Patients. Dis Markers 2017;2017:2176460. [PMID: 28684886 DOI: 10.1155/2017/2176460] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
47 Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. High Expression of FoxP1 Is Associated With Improved Survival in Patients With Non–Small Cell Lung Cancer. American Journal of Clinical Pathology 2012;138:230-5. [DOI: 10.1309/ajcpdhqfnyjz01yg] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.4] [Reference Citation Analysis]
48 Hu K, Shang J, Xie L, Hanyu M, Zhang Y, Yang Z, Xu H, Wang L, Zhang MR. PET Imaging of VEGFR with a Novel 64Cu-Labeled Peptide. ACS Omega 2020;5:8508-14. [PMID: 32337411 DOI: 10.1021/acsomega.9b03953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]